Investments in neurodegeneration-focused startups set to continue as Sanofi Ventures gets significant cash infusion.
Pharma giant Sanofi has revealed it is providing an additional $625 million to Sanofi Ventures, its corporate venture capital arm, with the funds earmarked for investments in early stage biotech and digital health. The multiyear capital infusion raises the evergreen fund’s assets under management to more than $1.4 billion, extending a decade-long strategy of identifying and nurturing early-stage companies in areas aligned with the French drugmaker’s long-term priorities.
The additional capital for its investment arm comes as the biotech sector faces constrained access to early funding, creating opportunities for well-capitalized investors to play a greater role in advancing high-risk, early-stage science.
“This new, significant capital commitment reflects our strong belief that some of the most important medical breakthroughs begin in early-stage companies,” said Sanofi CEO Paul Hudson. “By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.”
Among its varied biotech investments, Sanofi Ventures has a clear interest in longevity-related innovation, particularly when it comes to neurodegeneration. In 2021, it backed the launch of Muna Therapeutics, which is advancing small molecules designed to repair neuronal dysfunction and resolve neuroinflammation in Alzheimer’s and Parkinson’s disease.
Other recent investments reflect the firm’s interest in companies targeting age-related and neurodegenerative conditions:
- Character Biosciences, which extended its Series B to $110 million this month, is developing precision therapies for polygenic diseases, including age-related macular degeneration.
- Therini Bio is advancing candidates for Alzheimer’s disease and diabetic macular edema, and recently extended its Series A to $75 million.
- Nura Bio is building a pipeline of neuroprotective agents targeting axon degeneration and microglial activity, bolstered by last year’s $140 million Series A.
- And Sudo Biosciences upsized its Series B to $147 million last year, supporting its development of TYK2 inhibitors, including a brain-penetrant candidate with potential applications in multiple neurodegenerative disorders.
Sanofi has also moved to consolidate its bets, snapping up Vigil Neuroscience this summer after first committing $40 million as a strategic investor, acquiring a clinical stage program aimed at enhancing microglial neuroprotection in Alzheimer’s disease.
Sanofi Ventures says it has already deployed over $800 million since its launch in 2012, backing more than 70 companies worldwide.
“The strong performance of our fund, including three realized exits in 2024 from companies with a combined acquisition value of $3.25 billion, validates our evergreen structure and approach to identifying and supporting companies that are at the forefront of medical innovation,” said Sanofi Ventures boss Dr Jason P Hafler.
